Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: Breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection

Intervirology

Volumn 45, Issue 4-6, 2002, Pages 237-250

  Menne, Stephan ^a   Roneker, Carol A ^a   Tennant, Bud C ^a   Korba, Brent E ^b   Gerin, John L ^b   Cote, Paul J ^b  

^a Cornell University ^*  (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug antiviral therapy; Hepatitis B; Immunologic tolerance; In vivo animal models; Lymphocyte proliferation; Therapeutic vaccination; Woodchuck; Woodchuck hepatitis virus

Indexed keywords

CLEVUDINE; HEPATITIS ANTIBODY; HEPATITIS ANTIGEN; HEPATITIS B VACCINE; LIVER ENZYME; MEMBRANE ANTIGEN; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; HEPATITIS B; HEPATITIS VIRUS; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS CARRIER; VIRUS CORE; WOODCHUCK;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; IMMUNITY, CELLULAR; MARMOTA; VACCINATION;

ANIMALIA; HEPATITIS B VIRUS; MARMOTA MONAX; WOODCHUCK HEPATITIS B VIRUS;

EID: 0036983178     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067914     Document Type: Conference Paper

References (52)

1. Kane MA: Status of hepatitis B immunization programmes in 1998. Vaccine 1998;16(suppl):S104-S108.
2. Chisari FV: Rous-Whipple Award Lecture. Viruses, immunity, and cancer: Lessons from hepatitis B. Am J Pathol 2000;156:1117-1132.
3. Menne S, Tennant BC: Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). Nat Med 1999;10:1125-1126.
4. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, Petit MA, Fiaccadori F: Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990;145:3442-3449.
5. Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, Froesner G, Will H, Pape GR: Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995;69:3358-3368.
6. Löhr HF, Weber W, Schlaak J, Goergen B, Meyer zum Bueschenfelde KH, Gerken G: Proliferative response of CD4+ T-cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology 1995;22:61-68.
7. Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, Durazzo M, Missale G, Penna A, Fiaccadori F, Del Prete G, Ferrari C: Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997;112:193-199.
8. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A: Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;487:6599-6603.
9. Milich DR, Chen MK, Hughes JL, Jones JE: The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: A mechanism for persistence. J Immunol 1998;160:2013-2021.
10. Marinos G, Torre F, Chokshi S, Hussain M, Clarke BE, Rowlands DJ, Eddleston AL, Naoumov NV, Williams R: Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: A major factor in activation of the host immune response to the hepatitis B virus. Hepatology 1995;22:1040-1049.
11. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, Chang TH, Chen DS: Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992;89:87-96.
12. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C: Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.
13. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
14. Hoofnagle JH: Therapy of viral hepatitis. Digestion 1998;59:563-578.
15. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.
16. Marinos G, Naoumov NV, Williams R: Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996;24:991-995.
17. Pontesilli O, Van Nunen A, Van Riel D, Bruijns S, Niesters B, Uytdehaag F, De Man RA, Schalm SW, Osterhaus AD: Immune responses during lamivudine/interferon-α combination therapy of chronic HBV infection. Antivir Ther 2000;5(suppl 1):B18.
18. Fruttaldo L, Schettino G, Mongio F: Anti-HBV vaccination before therapy with interferon (IFN) in chronic B hepatitis. Eur Rev Med Pharmacol Sci 1997;1:197-201.
19. Kaymakoglu S, Demir K, Cakaloglu Y, Tuncer I, Dincer D, Gurel S, Okten A: Combination therapy with hepatitis B vaccine and interferon alfa in chronic hepatitis B. Am J Gastroenterol 1999;94:856-857.
20. Celis E, Ou D, Otvos L Jr: Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J Immunol 1988;140:1808-1815.
21. Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, Michel ML: Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999;180:15-26.
22. Deulofeut H, Iglesias A, Mikael N, Bing DH, Awdeh Z, Yunis J, Marcus-Bagley D, Kruskall MS, Alper CA, Yunis EJ: Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals. Mol Immunol 1993;30:941-948.
23. Ferrari C, Cavalli A, Penna A, Valli A, Bertoletti A, Pedretti G, Pilli M, Vitali P, Neri TM, Giuberti T, Fiaccadori F: Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology 1992;103:255-263.
24. Honorati MC, Dolzani P, Mariani E, Piacentini A, Lisignoli G, Ferrari C, Facchini A: Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 1997;112:2017-2027.
25. Hsu HY, Chang MH, Hsieh RP, Ni YH, Chi WK: Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen. Hepatology 1996;24:1355-1360.
26. Pol S, Couillin I, Michel ML, Driss F, Nalpas B, Carnot F, Berthelot P, Brechot C: Immunotherapy of chronic hepatitis B by anti HBV vaccine. Acta Gastroenterol Belg 1998;61:228-233.
27. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C: Efficacy of immunotherapy with vaccination against hepatitis B virus on virus B multiplication (in French). C R Acad Sci III 1993;316:688-691.
28. Cote PJ, Gerin JL: The woodchuck as a model of hepadnavirus infection, pathogenesis and therapy. Forum Trends Exp Clin Med 1996;6:131-159.
29. Roggendorf M, Tolle TK: The woodchuck: An animal model for hepatitis B virus infection in man. Intervirology 1995;38:100-112.
30. Tennant BC, Gerin JL: The woodchuck model of hepatitis B virus infection. ILAR J 2001;42:89-102.
31. Korba BE, Cote PJ, Hornbuckle WE, Tennant BC, Gerin JL: Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 2000;31:1165-1175.
32. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, Korba BE: Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001;33:254-266.
33. Cote PJ, Korba BE, Tennant BC, Gerin JL: Immunopathogenesis and immunomodulation of woodchuck hepatitis virus infection; in Hollinger FB, Lemon SM, Margolis HS (eds): Viral Hepatitis and Liver Disease. Baltimore, Williams & Wilkins, 1991, pp 483-486.
34. Gerin JL, Tennant BC, Popper H, Tyeryar FJ, Purcell RH: The woodchuck model of hepadnavirus infection and disease; in Brown F, Chanock R, Lerner R (eds): Vaccines, '86: New Approaches to Immunization - Developing Vaccines against Parasitic, Bacterial and Viral Diseases. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1986, pp 383-386.
35. Hervas-Stubbs S, Lasarte JJ, Sarobe P, Prieto J, Cullen JM, Roggendorf M, Borras-Cuesta F: Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol 1997;27:726-737.
36. Hervas-Stubbs S, Lasarte JJ, Sarobe P, Vivas I, Condreay L, Cullen JM, Prieto J, Borras-Cuesta F: T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol 2001;35:105-111.
37. Lu M, Hilken G, Kruppenbacher J, Kemper T, Schirmbeck R, Reimann J, Roggendorf M: Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol 1999;73:281-289.
38. Schodel F, Neckermann G, Peterson D, Fuchs K, Fuller S, Will H, Roggendorf M: Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection. Vaccine 1993;11:624-628.
39. Putzer BM, Stiewe T, Rodicker F, Schildgen O, Ruhm S, Dirsch O, Fiedler M, Damen U, Tennant BC, Scherer C, Graham FL, Roggendorf M: Large nontransplanted hepatocellular carcinoma in woodchucks: Treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J Natl Cancer Inst 2001;93:472-479.
40. Cote PJ, Gerin JL: In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: Implications for modeling immunity and therapy in hepatitis B virus infection. Hepatology 1995;22:687-699.
41. Cote PJ, Korba BE, Miller RH, Jacob JR, Baldwin BH, Hornbuckle WE, Purcell RH, Tennant BC, Gerin JL: Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 2000;31:190-200.
42. Cote PJ, Toshkov IA, Bellezza C, Ascenzi M, Roneker CA, Graham LA, Baldwin BH, Gaye K, Nakamura I, Korba BE, Tennant BC, Gerin JL: Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: Increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection. Hepatology 2000;32:807-817.
43. Guo JT, Zhou H, Liu C, Aldrich C, Saputelli J, Whitaker T, Barrasa MI, Mason WS, Seeger C: Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000;74:1495-1505.
44. Menne S, Maschke J, Tolle TK, Lu M, Roggendorf M: Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol 1997;71:65-74.
45. Menne S, Maschke J, Klaes R, Grosse-Wilde H, Roggendorf M: Cellular immune response of woodchucks to woodchuck hepatitis virus surface protein during acute WHV infection; in Rizzetto M, Gerin JL, Verme G (eds): Viral Hepatitis and Liver Disease. Turin, Minerva Medica, 1997, pp 453-457.
46. Menne S, Maschke J, Lu M, Grosse-Wilde H, Roggendorf M: T-cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J Virol 1998;72:6083-6091.
47. Menne S, Roneker CA, Gerin JL, Cote PJ, Tennant BC: Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 2002;76:1769-1780.
48. Hodgson PD, Michalak TI: Augmented hepatic interferon gamma expression and T-cell influx characterize acute hepatitis progressing to recovery and residual lifelong virus persistence in experimental adult woodchuck hepatitis virus infection. Hepatology 2001;34:1049-1059.
49. Nakamura I, Nupp JT, Cowlen M, Hall WC, Tennant BC, Casey JL, Gerin JL, Cote PJ: Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: Chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon-gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 2001;33:439-447.
50. Gerin JL, Faust RM, Holland PV: Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-d sera in rabbits. J Immunol 1975;115:100-105.
51. Cote PJ, Roneker CA, Cass K, Schoedel F, Peterson D, Tennant BC, De Noronha F, Gerin JL: New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol 1993;6:161-169.
52. Hornbuckle WE, Graham ES, Roth L, Baldwin BH, Wickenden C, Tennant BC: Laboratory assessment of hepatic injury in the woodchuck (Marmota monax). Lab Anim Sci 1985;35:376-381.